Insider Trading June 17, 2026 05:52 PM

BillionToOne CTO David Tsao Executes Pre-Arranged Stock Sale and Option Exercise

An analysis of the executive transaction, financial performance, and valuation metrics surrounding BillionToOne Inc.

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
BLLN

David Tsao, Chief Technology Officer of BillionToOne Inc., executed a series of transactions on June 15, 2026, involving the sale of company stock and the exercise of stock options. The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, generating approximately $2.05 million in proceeds. These transactions occur against a backdrop of strong financial performance for the company, though valuation metrics present a mixed picture for investors.

BillionToOne CTO David Tsao Executes Pre-Arranged Stock Sale and Option Exercise
BLLN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • David Tsao sold 19,900 shares under a Rule 10b5-1 plan established in March 2026, generating $2.05 million in proceeds.
  • BillionToOne reported Q1 2026 revenue of $108.4 million, an 84% year-over-year increase, with EPS of $0.34.
  • Guggenheim raised its price target to $120 following investor meetings, citing new private payor contracting wins.

David Tsao, serving as the Chief Technology Officer for BillionToOne, Inc. (NASDAQ:BLLN), executed a transaction involving the sale of 19,900 shares of the company's Class A Common Stock on June 15, 2026. The divestment generated proceeds totaling approximately $2.05 million. The shares were sold at prices fluctuating between $98.7417 and $104.472 per share. This sale was facilitated through a Rule 10b5-1 trading plan, which Mr. Tsao established on March 6, 2026.

Concurrently on June 15, 2026, Mr. Tsao acquired an additional 20,000 shares of Class A Common Stock. These shares were obtained through the exercise of stock options at a strike price of $2.80 per share, resulting in a total cost of $56,000. The options exercised were fully vested and exercisable at the time of the transaction.

Following these reported activities, Mr. Tsao's direct holding in BillionToOne's Class A Common Stock stands at 1,000 shares. Additionally, he retains a portfolio of 620,000 stock options. The insider transaction occurs while BillionToOne shares are trading at $99.26, a level that reflects strong momentum despite underlying valuation concerns. Analysis indicates the company appears overvalued at current levels, with the stock trading at a price-to-earnings ratio of 124.71. This high P/E ratio is noted relative to the company's near-term earnings growth trajectory.

Despite the valuation metrics, the company maintains a financial health score described as great. Over the last twelve months, BillionToOne reported impressive revenue growth of 100%. For comprehensive insights, investors can access BillionToOne's Pro Research Report, available through InvestingPro for this and over 1,400 other US equities.

Recent financial disclosures highlight robust results for the first quarter of 2026. The company reported a notable increase in both revenue and earnings, with earnings per share reaching $0.34, which surpassed market expectations. Revenue for the quarter climbed to $108.4 million, representing an 84% increase compared to the same period last year. These financial results were a focal point during investor meetings hosted by Guggenheim. Following these discussions, Guggenheim raised its price target for BillionToOne shares to $120 while maintaining a Buy rating. The meetings also highlighted new private payor contracting wins and improvements in the company's reimbursement position.

Additionally, BillionToOne held its annual meeting of stockholders, where shareholders elected two Class I directors. Oguzhan Atay and Akshay Rai were elected to serve until the 2029 annual meeting. This series of developments reflects BillionToOne's ongoing progress and strategic initiatives.

Risks

  • The stock trades at a high P/E ratio of 124.71 relative to near-term earnings growth, suggesting potential valuation concerns.
  • The company appears overvalued at current levels according to analysis, which may impact future stock performance.

More from Insider Trading

Anterix Legal Executive Offloads $1.44M in Shares Amid Post-Earnings Rally Jun 17, 2026 Insider Activity: Bechtolsheim Divests $43M in Arista Networks Amid Strong Analyst Sentiment Jun 17, 2026 Magnite Executives Adjust Holdings Amidst Market Momentum Jun 17, 2026 Hims & Hers Health CTO Mohamed Elshenawy Executes Pre-Arranged Stock Sale Jun 17, 2026 Hims & Hers Executive Irene Becklund Executes $370K Sale Under Pre-Set Plan Jun 17, 2026